ABCL
AbCellera Biologics·NASDAQ
--
--(--)
--
--(--)
4.68 / 10
Netural
Liquidity flow evaluation: 7.71/10 demonstrating robust fund flow characteristics. Optimistic no significant trends patterns are mitigated by pessimistic overall, block, Small, Medium, Large, and Extra-large indicators, pointing to positive flow perspective. The analyst community expresses divided analyst consensus with neutral perspective. Ratings composition: Neutral(100.0%) representing 1 analyst views, supported by 1.65 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-07
InstitutionLeerink Partners
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for ABCL?
- ABCL holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.68/10 (Netural).
